Stay updated on Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page.

Latest updates to the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedUpdated the study locations to include new sites in the United States (Arizona, Colorado, Kansas, Kentucky, Louisiana, New Hampshire, North Carolina, Ohio, Tennessee, Washington) and international sites (Buenos Aires, Mexico City, Nuevo León, San Luis Potosí, Sinaloa, Yucatán, Lesser Poland Voivodeship, Kemerovo Oblast, Novosibirsk Oblast, Tomsk Oblast, La Coruna, Malaga, Vizcaya). Some locations that appeared in the previous revision were removed.SummaryDifference2%

- Check19 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedRevision: v3.3.2 was added and v3.2.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check48 days agoChange DetectedRemoved the government funding lapse notice about potential delays; the page’s essential study information (eligibility criteria, locations, and treatment arms) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check63 days agoChange DetectedThe updates are minor UI/layout adjustments and small textual edits on the Study Details page. Core information such as the study title, NCT number, condition, intervention, and listed locations remains unchanged.SummaryDifference0.3%

- Check91 days agoChange DetectedCore content updated: a government funding and operating status notice has been added and the version updated to v3.2.0; the prior v3.1.0 tag was removed.SummaryDifference4%

- Check98 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tildrakizumab Long-Term Extension in Psoriatic Arthritis Clinical Trial page.